EUVIMEDEUVIMED entdecken
Crossref

Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL‐6 pathway through miR‐124

Helia Alavifard, Sogol Mazhari, Anna Meyfour, Samaneh Tokhanbigli, Saeid Ghavami, Mohammad Reza Zali, Hamid Asadzadeh Aghdaei, Behzad Hatami, Kaveh Baghaei

Cell Biology International · 2023

DOI: 10.1002/cbin.11992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Biology International, 2023. Verfasst von Helia Alavifard und 8 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Be…. Hauptthemen laut MEDLINE: Interleukin-6, MicroRNAs. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The activation of hepatic stellate cells is the primary function of facilitating liver fibrosis. Interfering with the coordinators of different signaling pathways in activated hepatic stellate cells (aHSCs) could be a potential approach in ameliorating liver fibrosis. Regarding the illustrated anti‐fibrotic effect of imatinib in liver fibrosis, we investigated the imatinib′s potential role in inhibiting HSC activation through miR‐124 and its interference with the STAT3/hepatic leukemia factor (HLF)/IL‐6 circuit. The anti‐fibrotic effect of imatinib was investigated in the LX‐2 cell line and carbon tetrachloride (CCl 4 )‐induced Sprague‐Dawley rat. The expression of IL‐6, STAT3, HLF, miR‐124, and α‐smooth muscle actin (α‐SMA) were quantified by quantitative real‐time PCR (qRT‐PCR) and the protein level of α‐SMA and STAT3 was measured by western blot analysis both in vitro and in vivo. The LX‐2 cells were subjected to immunocytochemistry (ICC) for α‐SMA expression. After administering imatinib in the liver fibrosis model, histopathological examinations were done, and hepatic function serum markers were checked. Imatinib administration alleviated mentioned liver fibrosis markers. The expression of miR‐124 was downregulated, while IL‐6/HLF/STAT3 circuit agents were upregulated in vitro and in vivo. Notably, imatinib intervention decreased the expression of IL‐6, STAT3, and HLF. Elevated expression of miR‐124 suppressed the expression of STAT3 and further inhibited HSCs activation. Our results demonstrated that imatinib not only ameliorated hepatic fibrosis through tyrosine kinase inhibitor (TKI) activity but also interfered with the miR‐124 and STAT3/HLF/IL‐6 pathway. Considering the important role of miR‐124 in regulating liver fibrosis and HSCs activation, imatinib may exert its anti‐fibrotic activity through miR‐124.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6MicroRNAsRatsAnimalsImatinib MesylateHepatic Stellate CellsRats, Sprague-DawleyLiver CirrhosisCarbon Tetrachloride

Stichwörter der Autor:innen

IL-6STAT3hepatic leukemia factorimatinibliver fibrosismiR-124

Substanzen

Imatinib MesylateInterleukin-6MicroRNAsCarbon TetrachlorideMIRN124 microRNA, rat

Autor:innen und Institutionen

  • Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
  • Research Institute in Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Autophagy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Faculty of Medicine, Katowice School of Technology, Katowice, Poland.
  • Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Förderung

  • Shahid Beheshti University of Medical Sciences

Zitieren

APA

Alavifard, H., Mazhari, S., Meyfour, A., Tokhanbigli, S., Ghavami, S., Zali, M. R., Aghdaei, H. A., Hatami, B., & Baghaei, K. (2023). Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL‐6 pathway through miR‐124. Cell Biology International. https://doi.org/10.1002/cbin.11992

Vancouver

Alavifard H, Mazhari S, Meyfour A, Tokhanbigli S, Ghavami S, Zali MR, et al. Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL‐6 pathway through miR‐124. Cell Biology International. 2023. doi:10.1002/cbin.11992

BibTeX
@article{Alavifard2023,
  author = {Alavifard, Helia and Mazhari, Sogol and Meyfour, Anna and Tokhanbigli, Samaneh and Ghavami, Saeid and Zali, Mohammad Reza and Aghdaei, Hamid Asadzadeh and Hatami, Behzad and Baghaei, Kaveh},
  title = {Imatinib suppresses activation of hepatic stellate cells by targeting STAT3/IL‐6 pathway through miR‐124},
  journal = {Cell Biology International},
  year = {2023},
  doi = {10.1002/cbin.11992}
}
Kostenlos starten →